Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 70
- Registration Number
- NCT02743819
- Locations
- ๐บ๐ธ
Oncology Specialists S.C., Park Ridge, Illinois, United States
๐บ๐ธUniversity of South Alabama, Mobile, Alabama, United States
๐บ๐ธMount Sinai Medical Center of Florida, Miami Beach, Florida, United States
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
- Conditions
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 166
- Registration Number
- NCT02737475
- Locations
- ๐บ๐ธ
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
๐ฎ๐นIRCCS Istituto Nazionale Tumori Milano, Milano, Italy
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Parker Institute for Cancer Immunotherapy
- Target Recruit Count
- 20
- Registration Number
- NCT02731729
- Locations
- ๐บ๐ธ
Lehigh Valley Health Network, Allentown, Pennsylvania, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02723006
- Locations
- ๐บ๐ธ
Emory University Hospital, Atlanta, Georgia, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธTexas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 196
- Registration Number
- NCT02703623
- Locations
- ๐บ๐ธ
MD Anderson in Katy, Houston, Texas, United States
๐บ๐ธM D Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธMD Anderson in Sugar Land, Sugar Land, Texas, United States
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT02696993
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 35
- Registration Number
- NCT02681302
- Locations
- ๐บ๐ธ
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
๐บ๐ธHackensack University medical Center, Hackensack, New Jersey, United States
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT02668770
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 73
- Registration Number
- NCT02662725
- Locations
- ๐ซ๐ท
AP-HM Hรดpital de la Timone, Marseille, France
๐ซ๐ทCHU de Caen, Caen, France
๐ซ๐ทHรดpital Saint Eloi, Montpellier, France
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
- Conditions
- Interventions
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 627
- Registration Number
- NCT02658890
- Locations
- ๐บ๐ธ
Local Institution - 0057, Pittsburgh, Pennsylvania, United States
๐ซ๐ทLocal Institution - 0022, Villejuif, France
๐บ๐ธLocal Institution - 0033, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.